Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Phase 3 SOPHIA study of margetuximab plus chemotherapy vs trastuzumab plus chemotherapy in patients with HER2+metastatic breast cancer after prior anti-HER2 therapies: second interim overall survival analysis Rugo, H. S., Im, S., Cardoso, F., Cortes, J., Curigliano, G., Pegram, M. D., Musolino, A., Bachelot, T., Wright, G. S., De laurentiis, M., Kaufman, P. A., Pluard, T., Ricci, F., Salazar, L. G., Yardley, D. A., Edlich, S., Hong, S., Rock, E., Gradishar, W. J., SOPHIA Study Grp AMER ASSOC CANCER RESEARCH. 2020
View details for DOI 10.1158/1538-7445.SABCS19-GS1-02
View details for Web of Science ID 000527012500025